Additionally, PI3K/AKT/mTOR signaling pathway dysregulation is frequently identified in patients with RCC, and mTOR inhibitors, including everolimus and temsirolimus, are effective in metastatic ccRCC [24]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.